Vivoryon Therapeutics N.V. (05Y)

Overview

Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule medicines. Established in 1997 and based in Halle, Germany, the company is advancing therapeutic solutions targeting diseases associated with toxic protein aggregates. Primarily concentrating on neurodegenerative diseases like Alzheimer's, Vivoryon's research is anchored on blocking the formation of toxic pyroglutamate-Abeta (pGlu-Abeta), a variant of amyloid-beta linked to the progression of Alzheimer's. Collaborations with Nordic Bioscience, Fraunhofer Institute for Cell Therapy and Immunology, and Simcere Pharmaceutical Group Ltd highlight its commitment to advancing Alzheimer's research and therapy solutions, showcasing a blend of in-house development and strategic partnerships to expand its clinical and commercial reach.

Products and Services

• PQ912

  A leading product candidate from Vivoryon, PQ912, stands out as a nanomolar inhibitor targeting QPCT (Glutaminyl cyclase), pivotal in the production of pGlu-Abeta. Having completed Phase IIb clinical trials, its development is aimed primarily at the treatment of Alzheimer's disease. The innovation around PQ912 demonstrates Vivoryon's targeted approach in addressing the critical pathways involved in the pathogenesis of Alzheimer’s, offering a potential breakthrough in a therapy area that has seen limited advancement over the years.

• PBD-C06

  In addition to PQ912, the company is developing PBD-C06, a monoclonal antibody focused on N3pE-Abeta, another neurotoxic variant of amyloid-beta implicated in Alzheimer's disease. This product represents Vivoryon's exploration into biologics, diversifying their portfolio towards a comprehensive approach in combating Alzheimer's disease by neutralizing different forms of toxic amyloid-beta species.

• Collaborations for Clinical Development

  Vivoryon has entered into a collaboration agreement with Nordic Bioscience concerning the clinical development of PQ912 for Alzheimer's. This partnership signifies the company's efforts to leverage external expertise and resources to accelerate the development and potential commercialization phases of its leading compound. Further extending its collaborative efforts, Vivoryon has teamed up with the Fraunhofer Institute for Cell Therapy and Immunology for research collaborations, enhancing its scientific foundation and research capabilities. Additionally, a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd focuses on developing and commercializing treatments targeting N3pE (pGlu-Abeta) for Alzheimer's disease in specific markets, showcasing Vivoryon's strategy to widen its global footprint through strategic alliances.